Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab

Scaramucci, Laura; Perrotti, Alessio; Niscola, Pasquale; Fratoni, Stefano; Palombi, Massimiliano; Piccioni, Daniela; Cupelli, Luca; Tendas, Andrea; Dentamaro, Teresa; Poeta, Giovanni Del; Fabritiis, Paolo de

doi:10.1080/10428190701509814

Cited by 6 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports have indicated that the treatment of B‐NHL with rituximab may be associated with CD20‐negative lymphoma relapse, ( 5–17 ) and the frequency of loss of CD20 after rituximab treatment varies widely (24, 56, 60, and 94%). ( 9,11,13,14 ) In the present study, 16 of 59 B‐NHL (27%) showed loss of CD20 after rituximab‐containing therapy using a larger series than in previous reports.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have reported that B‐NHL show CD20‐negative relapse after rituximab therapy. ( 5–17 ) Transformation of follicular lymphoma (FL) to CD20‐negative diffuse large B‐cell lymphoma (DLBCL), ( 15 ) proliferation of CD20‐negative plasmacytoid tumor cells of marginal zone B‐cell lymphoma (MZBCL) ( 16 ) or lymphoplasmacytic lymphoma, ( 13 ) transformation of FL to classical Hodgkin's lymphoma, ( 17 ) and progression of nodular lymphocyte‐predominant Hodgkin lymphoma to CD20‐negative T‐cell‐rich B‐cell lymphoma have also been reported. ( 18 )…”

mentioning

confidence: 99%

See 1 more Smart Citation

Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy

Maeshima¹,

Taniguchi²,

Nomoto

et al. 2009

Cancer Science

View full text Add to dashboard Cite

Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen. It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern. We examined histological and immunohistochemical changes in 59 patients with B-NHL after rituximab therapy. The patients comprised 32 men and 27 women with a median age of 59 years. Pre-rituximab specimens comprised 34 follicular lymphomas (FL), 11 diffuse large B-cell lymphomas (DLBCL), 10 mantle cell lymphomas, two marginal zone B-cell lymphomas (MZBCL), and two chronic lymphocytic leukemias (CLL). CD20 expression in lymphoma cells was evaluated by immunohistochemistry or flow cytometry. Postrituximab materials were taken a median of 6 months (4 days to 59 months) after rituximab therapy. Sixteen cases ( R ituximab is a chimeric monoclonal antibody that has recently been incorporated into the treatment of B-cell non-Hodgkin lymphoma (B-NHL). It recognizes the CD20 antigen, a pan-B-cell marker, binds to it, and induces apoptosis of CD20-positive cells.(1-4) Rituximab can be used as a monotherapy or in combination with conventional chemotherapy for treatment of low-and high-grade, untreated, relapsed, or refractory CD20-positive B-NHL, achieving a high response rate with a low toxicity.Recent studies have reported that B-NHL show CD20-negative relapse after rituximab therapy.(5-17) Transformation of follicular lymphoma (FL) to CD20-negative diffuse large B-cell lymphoma (DLBCL), (15) proliferation of CD20-negative plasmacytoid tumor cells of marginal zone B-cell lymphoma (MZBCL) (16) or lymphoplasmacytic lymphoma,transformation of FL to classical Hodgkin's lymphoma, (17) and progression of nodular lymphocyte-predominant Hodgkin lymphoma to CD20-negative T-cell-rich B-cell lymphoma have also been reported. (18) Several mechanisms of resistance to rituximab have been suggested, including selection of a CD20-negative clone as a consequence of rituximab exposure, masking of CD20 epitopes by rituximab itself, or true loss of CD20 antigen by genetic and epigenetic changes. (12,13,15,(19)(20)(21)(22)(23)(24) In the present study we carried out retrospective analyses of histological and immunophenotypic changes and outcome in 59 patients with B-NHL after rituximab-containing therapy, to explore the effect of rituximab on CD20 expression and morphology in B-NHL. Materials and MethodsPatient selection. We reviewed the pathology archives of the National Cancer Center Hospital, Tokyo, Japan, for the period 2002 to 2007. Fifty-nine consecutive cases of CD20-positive B-NHL treated with rituximab, with or without chemotherapy, for which pre-and post-rituximab specimens were available, were included in our study. Rituximab (Zenyaku Kogyo, Tokyo, Japan) was used at a standard dose of 375 mg/m 2 once a week for rituximab monotherapy and once every 3 weeks for the rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen. Clinical information was extracted from the medical records, and the Ann Arbor syste...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy

Maeshima¹,

Taniguchi²,

Nomoto

et al. 2009

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Although Hodgkin lymphoma (HL) can develop in patients with B-cell follicular lymphoma (FL) [1,2], especially after treatment, and some cases of coexisting histological features of HL and FL (composite lymphoma) [3Á5] has been described, the truly occurrence of a FL following a HD [6], as recently observed by us, has been very rarely reported so far. Indeed, we recently encountered an unusual sequence of lymphoid tumors in the same patient; indeed, after a long lasting recovery from a classical HL, he presented a FL subsequently evolved in a diffuse large B-cells lymphoma (DLBCL).…”

Section: To the Editormentioning

confidence: 99%

“…Being diagnosed with cancer imposes a challenge to emotional adjustment, and many cancer patients have been found to suffer from existential distress [1,2]. As existential distress does not reflect pathology, but is a condition that arises out of life circumstances, the suffering may respond well to an unstructured supportive interaction with caring providers [1].…”

Section: Department Of Oncology Aarhus University Hospital Denmarkmentioning

confidence: 99%

See 1 more Smart Citation

Unusual sequence of lymphoid disorders: Follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma

et al. 2009

Self Cite

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab

Cited by 6 publications

References 6 publications

Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy

Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy

Unusual sequence of lymphoid disorders: Follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About